Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug DevelopmentPsyence Group2024-08-27T10:00:50+02:00August 13, 2024|Read More
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLCPsyence Group2024-08-27T09:55:48+02:00August 2, 2024|Read More
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb TrialPsyence Group2024-08-27T14:01:21+02:00July 25, 2024|Read More
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company ShowcasePsyence Group2024-08-27T09:57:50+02:00May 17, 2024|Read More
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)Psyence Group2024-08-27T09:58:34+02:00April 18, 2024|Read More
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin TrialPsyence Group2024-08-27T10:00:45+02:00April 9, 2024|Read More
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic PsilocybinPsyence Group2024-08-27T10:11:57+02:00March 21, 2024|Read More
Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future MilestonesPsyence Group2024-08-27T10:12:04+02:00March 12, 2024|Read More
Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb StudyPsyence Group2024-08-27T10:12:14+02:00March 7, 2024|Read More
